Results 161 to 170 of about 104,102 (262)

The influence of early intravenous immunoglobulin administration on the prognosis of severe hemolytic disorders in neonates. [PDF]

BMC Pediatr
Zhu D, Zhou Q, Yu B, Chen C.
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Acute Hemorrhagic Necrotizing Encephalopathy in a COVID-19 Patient With a Response to Intravenous Immunoglobulin Therapy. [PDF]

Am J Case Rep
Almeer FS, Alkoheji HK, Zayed ME, Al-Hilly AJ, Abduljabar Hussein O.   +4 more
europepmc   +1 more source

HOME INTRAVENOUS IMMUNOGLOBULIN THERAPY

The Lancet, 1988
Chapel, H, Brennan, V
openaire   +3 more sources

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database. [PDF]

Curr Ther Res Clin Exp
Susini D, Crea R, Morabito P, Kleyn A, Bizzarri A.   +4 more
europepmc   +1 more source

Intravenous immunoglobulin for cutaneous chronic graft-versus-host disease. [PDF]

JAAD Case Rep
Chang TH, Greif T, Nayar J, Cardones AR.
europepmc   +1 more source

Value of peripheral blood cell parameters and their derived ratios in predicting intravenous immunoglobulin resistance in Kawasaki disease. [PDF]

Ital J Pediatr
Tang Q, Xu X, Gan C.
europepmc   +1 more source

Management of ring chromosome 20 syndrome: Narrative review and consensus recommendations

Epilepsia, EarlyView.
Abstract Ring chromosome 20 (ring 20) is a rare genetic condition usually presenting as developmental and epileptic encephalopathy. The disease is caused by fusion of the long and short arms of chromosome 20. Patients are symptomatic even if there is no loss of genetic material.
Asma Khamis, Emilia Ricci, Maria Paola Canevini, Lieven Lagae, Kentaro Tokumoto, Yushi Inoue, Tim Buckinx, Allison Watson, Kenneth A. Myers   +8 more
wiley   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies. [PDF]

Br J Clin Pharmacol
Cheng IL, Huang ZH, Worth A, Booth C, Standing JF.   +4 more
europepmc   +1 more source